Repositorio Dspace

Predictors of relapse following transition to ofatumumab in relapsing-remitting multiple sclerosis

Mostrar el registro sencillo del ítem

dc.contributor.author Reardon, Patrick
dc.contributor.author Zhong, Michael
dc.contributor.author Horakova, Dana
dc.contributor.author Kermode, Allan-G
dc.contributor.author Fabis-Pedrini, Marzena
dc.contributor.author Vachova, Marta
dc.contributor.author Prevost, Julie
dc.contributor.author Lechner-Scott, Jeannette
dc.contributor.author van-der-Walt, Anneke
dc.contributor.author Pavelek, Zbysek
dc.contributor.author Stourac, Pavel
dc.contributor.author Stetkarova, Ivana
dc.contributor.author Meca-Lallana, José-Eustasio
dc.contributor.author McCombe, Pamela
dc.contributor.author Gross-Paju, Katrin
dc.contributor.author Millan-Pascual, Jorge
dc.contributor.author Kalincik, Tomas
dc.contributor.author Roos, Izanne
dc.contributor.author Lapointe, Emmanuelle
dc.contributor.author Houskova, Jana
dc.contributor.author Recmanova, Eva
dc.contributor.author Peterka, Marek
dc.contributor.author Ampapa, Radek
dc.contributor.author Jakob, Gregor-Brecl
dc.contributor.author Foschi, Matteo
dc.contributor.author Jokubaitis, Vilija
dc.contributor.author Butzkueven, Helmut
dc.date.accessioned 2026-11-11T09:05:37Z
dc.date.available 2026-11-11T09:05:37Z
dc.date.issued 2026-11
dc.identifier.citation Reardon P, Zhong M, Horakova D, Kermode AG, Fabis-Pedrini M, Vachova M, et al. Predictors of relapse following transition to ofatumumab in relapsing-remitting multiple sclerosis. Multiple Sclerosis and Related Disorders. noviembre de 2026;115:107981. doi:10.1016/j.msard.2026.107981
dc.identifier.issn 2211-0348
dc.identifier.uri https://sms.carm.es/ricsmur/handle/123456789/29180
dc.description.abstract INTRODUCTION: Ofatumumab (OFA) is an emerging therapy for relapsing-remitting multiple sclerosis (RRMS), but the impact of prior disease-modifying therapy (pDMT) on outcomes after switching is unclear. OBJECTIVES: To evaluate predictors of first-year relapse after switching from selected pDMTs to OFA in adults with RRMS enrolled in the MSBase Registry. RESULTS: Among 866 patients (median EDSS 2.5), 10.5% experienced a relapse in the first year on OFA. Switching from fingolimod was associated with higher relapse risk compared to switching from injectable therapies (HR 1.89, 95% CI 1.03-3.44, p?=?0.038). Higher EDSS at OFA initiation (HR 1.25, 95% CI 1.09-1.43, p?=?0.001) and relapse in the year prior to pDMT cessation (HR 1.75, 95% CI 1.01-3.03, p?=?0.045) also predicted relapse. Washout period duration was not associated with relapse in the overall cohort, but longer washout among fingolimod switchers increased relapse risk (HR 1.34, 95% CI 1.01-1.79, p?=?0.044). CONCLUSION: Relapse after switching to OFA is influenced by baseline disability, recent relapse, and prior fingolimod use. Shorter washout may reduce relapse risk in fingolimod switchers. These findings support tailored monitoring and further research to optimise treatment transitions in RRMS.
dc.language.iso eng
dc.publisher ELSEVIER SCI LTD
dc.rights Atribución/Reconocimiento 4.0 Internacional
dc.rights.uri https://creativecommons.org/licenses/by/4.0/deed.es *
dc.subject.mesh Humans
dc.subject.mesh Multiple Sclerosis, Relapsing-Remitting/drug therapy/diagnosis
dc.subject.mesh Female
dc.subject.mesh Antibodies, Monoclonal, Humanized/therapeutic use
dc.subject.mesh Adult
dc.subject.mesh Recurrence
dc.subject.mesh Male
dc.subject.mesh Registries
dc.subject.mesh Fingolimod Hydrochloride/therapeutic use
dc.subject.mesh Immunologic Factors/therapeutic use
dc.subject.mesh Drug Substitution
dc.subject.mesh Middle Aged
dc.subject.mesh Immunosuppressive Agents/therapeutic use
dc.title Predictors of relapse following transition to ofatumumab in relapsing-remitting multiple sclerosis
dc.type info:eu-repo/semantics/article
dc.identifier.pmid 42874502
dc.relation.publisherversion https://linkinghub.elsevier.com/retrieve/pii/S2211034826010163
dc.type.version info:eu-repo/semantics/publishedVersion
dc.identifier.doi 10.1016/j.msard.2026.107981
dc.journal.title Multiple Sclerosis and Related Disorders
dc.identifier.essn 2211-0356


Ficheros en el ítem

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Atribución/Reconocimiento 4.0 Internacional Excepto si se señala otra cosa, la licencia del ítem se describe como Atribución/Reconocimiento 4.0 Internacional

Buscar en DSpace


Búsqueda avanzada

Listar

Mi cuenta